A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Renal Cell Carcinoma
Interventions
DRUG

Bevacizumab

"* First treatment: 10 milligram per kilograms (MG/KG) intravenously (IV) on Day 1every two weeks over 90 minutes.~* Second treatment: 10 MG/KG IV on Day 1 every two weeks over 60 minutes.~* Third and subsequent treatments: 10 MG/KG IV on Day 1 every two weeks over 30 minutes (minimum of two cycles)."

DRUG

Azacitidine

"* Dose level 1: 35 mg/m2/day for 7 days.~* Dose level 2: 55 mg/m2/day for 7 days.~* Dose level 3: 75 mg/m2/day for 7 days.~ * mg/m2/day = dose based on height and weight"

Trial Locations (2)

66160

University of Kansas Medical Center, Kansas City

66606

Stormont-Vail Cotton O'Neil Cancer Center, Topeka

Sponsors

Collaborators (1)

All Listed Sponsors
lead

University of Kansas Medical Center

OTHER

collaborator

Celgene

INDUSTRY